Results 171 to 180 of about 3,049 (238)

Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study. [PDF]

Drugs Real World Outcomes
Parhofer KG, Bramlage P, Gries C, Harder C, Look C, Paar WD, Rauch-Kröhnert U.   +6 more
europepmc   +1 more source

Editorial: Gene therapy and genome editing for metabolic liver disorders. [PDF]

Front Mol Med
Collaud F, Bortolussi G.
europepmc   +1 more source

Supravalvular Aortic Stenosis in Homozygous Familial Hypercholesterolemia: Contemporary Management. [PDF]

JACC Case Rep
Eisenberg S, Gold D, Mehta PK, Leshnower B, Sperling LS.   +4 more
europepmc   +1 more source

Clinical characteristics and favorable treatment responses of recurrent focal segmental glomerulosclerosis or steroid-resistant nephrotic syndrome in children after kidney transplantation. [PDF]

Pediatr Nephrol
Dharnidharka VR, Scobell RR, Kallash M, Davies AJG, Marchesani N, Maltenfort MG, Walther L, Kelton M, Bock M, Blanchette E, Stone HK, Gluck C, Hullekes F, Riella LV, Smoyer WE, Mitsnefes M, Dixon BP, Flynn JT, Somers MJG, Forrest CB, Furth S, Denburg MR.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Hypercholesterolemia and LDL Apheresis

The International Journal of Artificial Organs, 2005
Several trials have assessed the link between low-density lipoprotein cholesterol (LDL) and the development of coronary heart disease (CHD). LDL apheresis provides an effective role in treating patients with familial hypercholesterolemia (FH) and in preventing the progression of coronary artery disease (CAD). Five different techniques of LDL apheresis
F. Morelli, P. Carlier, G. Giannini, M.C. De Luigi, A. Dejana, M.R. Ruzzenenti, M. Valbonesi   +6 more
openaire   +3 more sources

LDL apheresis in Japan

Transfusion and Apheresis Science, 2017
LDL apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH). Currently, plasma exchange, double membrane filtration, and selective LDL adsorption are available in Japan, and selective LDL adsorption is most common method. LDL apheresis can prevent atherosclerosis progression even in homozygous (HoFH). However, in
Tamiko Tamanaha, Hisashi Makino, Mariko Harada-Shiba   +2 more
openaire   +3 more sources

Immunosorbents for LDL-Apheresis

Biomaterials, Artificial Cells and Artificial Organs, 1990
Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation.
I. Yu. Adamova, G. F. Benevolenskaya, S.N. Pokrovsky   +2 more
openaire   +3 more sources

Pleiotropic effects of LDL apheresis

Atherosclerosis Supplements, 2009
LDL apheresis (LA), a technique employed to remove atherogenic lipoproteins, has been shown to exert a protective function on the vessel walls. This effect can be attributed to pleiotropic mechanisms that safeguard against endothelial dysfunction by reducing the concentrations of pro-inflammatory and pro-coagulation markers.
Paola Brescia, Alfonso Ramunni, Lucia Vernò, Maria Domenica Burzo   +3 more
openaire   +3 more sources

An update on LDL apheresis for nephrotic syndrome [PDF]

Pediatric Nephrology, 2018
Low-density lipoprotein (LDL) apheresis has been used increasingly in clinical practice for the treatment of renal diseases with nephrotic syndrome (NS), specifically focal segmental glomerulosclerosis (FSGS). Persistent hyperlipidemia for prolonged periods is nephrotoxic and leads to chronic progressive glomerular and tubulointerstitial injury ...
Rupesh Raina, Rupesh Raina, Vinod Krishnappa, Vinod Krishnappa   +3 more
openaire   +2 more sources